Novavax, Inc. (NVAX)

3,8900 -0,1000 (-2,51%) Alla chiusura: 04:00PM EDT

Novavax, Inc.

700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 1.543

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. John Joseph Trizzino B.S., M.B.A.	President & COO	641,22k	N/D	1960
Mr. James Patrick Kelly C.F.A.	Executive VP, CFO & Treasurer	644,32k	N/D	1966
Mr. Stanley Charles Erck	Advisor	1,09M	N/D	1948
Mr. John Charles Jacobs M.B.A.	CEO & Director	N/D	N/D	1967
Mr. Richard P. Crowley	Executive VP & COO	N/D	N/D	1957
Mr. Troy Morgan Esq., J.D.	Senior VP & Chief Compliance Officer	N/D	N/D	1971
Mr. Mark Casey	Executive VP, Chief Legal Officer & Corporate Secretary	N/D	N/D	N/D
Ms. Erika S. Trahan	Associate Director of Investor & Public Relations	N/D	N/D	N/D
Mr. Ian J. Watkins	Executive VP & Chief Human Resources Officer	N/D	N/D	1963
Ms. Silvia Taylor M.B.A.	Executive VP and Chief Corporate Affairs & Advocacy Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Governance aziendale

L'ISS Governance QualityScore di Novavax, Inc. al 1 aprile 2024 è 4. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 4; diritti degli azionisti: 5; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.